Prognos Health, formerly Medvio, is a healthcare company using artificial intelligence to help track and predict the onset of human diseases that is headquartered in New York City, New York and was founded in 2010 by Destry Sulkes, Jason Bhan, and Sundeep Bhan. The company's platform offers a method of extracting clinical insights from patient and provider data using data analytics. Prognos Health uses a registry of data containing information on more than 50 disease conditions (including diabetes, dyslipidemia, hepatitis C, gout, low testosterone, irritable bowel disease, hereditary angioedema, and chronic myelogenous leukemia), 29 billion lab records, 250 million patients in compliance with HIPAA, and over 1000 algorithms. The platform is used to serve several segments of the healthcare industry such as pharmaceuticals, healthcare providers, and healthcare payers.
On August 18, 2011 Prognos Health announced receiving a convertible note worth $745, 000 from Tom Nicholson.
On November 17. 2011 Prognos Health announced raising prices $7 million in series A funding from Safeguard Scientifics (lead investor), MentorTech Ventures, and ARC Angel Fund. The company plans on using their series A funding to expand its sales and marketing efforts, and to allocate more funding for product development.
On June 17, 2013 Prognos Health announced raising $15 million in series B funding from Merck Global Health Innovation Fund (lead investor), Safeguard Scientifics, and MentorTech Ventures.
On November 27, 2017 Prognos Health announced raising $20.5 million in series C funding from SafeGuard Scientifics, Merck Global Health Innovation Fund, Maywic Select Investments, Hikma Ventures, Hermed Capital, Guardian Life, and Cigna. The co-founder and CEO of Prognos Health, Sundeep Bhan, made the following statements regarding the company's series C funding:
For Prognos, Series C is a focused and disciplined effort to build on our success to scale the business as we pursue our mission of predicting disease earlier to drive better outcomes for patients. We view this round as a vote of confidence from the healthcare industry experts and global investment firms that understand the space well and believe that Prognos can continue to lead in providing early insights to deliver better patient care and lower costs.